Ernst M, Giubellino A. The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. Biomedicines. 2022;10(4):4. https://doi.org/10.3390/biomedicines10040822.

Article  CAS  Google Scholar 

Kahlon N, et al. Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. JAMA Netw Open. 2022;5(12):e2245269. https://doi.org/10.1001/jamanetworkopen.2022.45269.

Article  PubMed  PubMed Central  Google Scholar 

Melanoma of the Skin - Cancer Stat Facts,” SEER. Accessed: Dec. 08, 2023. [Online]. Available: https://seer.cancer.gov/statfacts/html/melan.html.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | NEJM. Accessed: Oct. 05, 2023. [Online]. Available: https://www.nejm.org/doi/full/10.1056/nejmoa1003466.

Mamoor M, et al. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000260. https://doi.org/10.1136/jitc-2019-000260.

Article  PubMed  PubMed Central  Google Scholar 

Rogiers A, et al. Psychosocial outcome and health-related quality of life (HRQoL) in advanced melanoma survivors. JCO. 2018;36(7_suppl):162–162. https://doi.org/10.1200/JCO.2018.36.7_suppl.162.

Article  Google Scholar 

Tolstrup LK, Pappot H, Bastholt L, Möller S, Dieperink KB. Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial. J Patient-Reported Outcomes. 2022;6(1):8. https://doi.org/10.1186/s41687-022-00414-5.

Article  Google Scholar 

Sitlinger A, Yousuf Zafar S. Health-Related Quality of Life. Surg Oncol Clin N Am. 2018;27(4):675–84. https://doi.org/10.1016/j.soc.2018.05.008.

Article  PubMed  PubMed Central  Google Scholar 

C. for D. E. and Research, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Accessed: Oct. 10, 2023. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims.

Aaronson NK, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76. https://doi.org/10.1093/jnci/85.5.365.

Article  CAS  PubMed  Google Scholar 

Cocks K, et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 2023;178:128–38. https://doi.org/10.1016/j.ejca.2022.10.026.

Article  PubMed  Google Scholar 

Scott NW et al. EORTC QLQ-C30 Reference Values Manual, 2008, Accessed: Oct. 10, 2023. [Online]. Available: https://abdn.elsevierpure.com/en/publications/eortc-qlq-c30-reference-values-manual.

Schadendorf D, et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017;82:80–91. https://doi.org/10.1016/j.ejca.2017.05.031.

Article  PubMed  PubMed Central  Google Scholar 

Revicki DA, et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes. 2012;10(1):66. https://doi.org/10.1186/1477-7525-10-66.

Article  PubMed  PubMed Central  Google Scholar 

Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med. 1997;16(11):1197–209. https://doi.org/10.1002/(sici)1097-0258(19970615)16:11%3c1197::aid-sim531%3e3.0.co;2-9.

Article  CAS  PubMed  Google Scholar 

Ford I, Norrie J. Pragmatic Trials. N Engl J Med. 2016;375(5):454–63. https://doi.org/10.1056/NEJMra1510059.

Article  PubMed  Google Scholar 

Aamdal E, et al. Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment. ESMO Open. 2022;7(5):100588. https://doi.org/10.1016/j.esmoop.2022.100588.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019;54(2):407–19. https://doi.org/10.3892/ijo.2018.4661.

Article  CAS  PubMed  Google Scholar 

Ramos-Casals M, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38. https://doi.org/10.1038/s41572-020-0160-6.

Article  PubMed  PubMed Central  Google Scholar 

Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158–68. https://doi.org/10.1056/NEJMra1703481.

Article  CAS  PubMed  Google Scholar 

Johnson DB, Chandra S, Sosman JA. Immune Checkpoint Inhibitor Toxicity in 2018. JAMA. 2018;320(16):1702–3. https://doi.org/10.1001/jama.2018.13995.

Article  PubMed  Google Scholar 

•• Naidoo J, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11(3):e006398. https://doi.org/10.1136/jitc-2022-006398. SITC definitions of chronic irAEs, persistent irAEs and de-novo irAEs.

Article  PubMed  PubMed Central  Google Scholar 

•• Patrinely JR Jr, et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021;7(5):744–8. https://doi.org/10.1001/jamaoncol.2021.0051. Largest study on chronic irAEs- a retrospective multicenter cohort study, conducted between 2015 and 2020 across 8 academic medical centers outlining chronic irAEs.

Article  PubMed  Google Scholar 

•• Goodman RS, et al. Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma. JAMA Netw Open. 2023;6(8): e2327145. https://doi.org/10.1001/jamanetworkopen.2023.27145. Updated analysis of the Patrinely article above with longer follow up.

Article  PubMed  PubMed Central  Google Scholar 

• Schulz TU, et al. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients’ health-related quality of life. Eur J Cancer. 2022;176:88–99. https://doi.org/10.1016/j.ejca.2022.08.029. A multicentre, cross-sectional study comprised 200 patients with cancer ≥12 weeks after ICI cessation (ICI-patients) and 2705 patients with autoimmune diseases and compared their quality of life and found patients had persistent irAEs that were similar to patients with autoimmune disease.

Article  CAS  PubMed  Google Scholar 

Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid. 2020;30(10):1458–69. https://doi.org/10.1089/thy.2020.0032.

Article  CAS  PubMed  Google Scholar 

Faje A, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019;181(3):211–9. https://doi.org/10.1530/EJE-19-0238.

Article  CAS  PubMed  Google Scholar 

Eggermont AMM, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789–801. https://doi.org/10.1056/NEJMoa1802357.

Article  CAS  PubMed  Google Scholar 

•• de Filette J, Andreescu CE, Cools F, Bravenboer B, Velkeniers B. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res. 2019;51(3):145–56. https://doi.org/10.1055/a-0843-3366. Systematic review and meta-analysis outlining the incidence of endocrine irAEs.

Article  CAS  PubMed  Google Scholar 

Martella S, et al. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects. Semin Oncol. 2023;50(6):144–8. https://doi.org/10.1053/j.seminoncol.2023.11.003.

Article  CAS  PubMed  Google Scholar 

Jeffrey W, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824–35. https://doi.org/10.1056/NEJMoa1709030.

Article  Google Scholar 

Barroso-Sousa R, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(2):173–82. https://doi.org/10.1001/jamaoncol.2017.3064.

Article  PubMed  Google Scholar 

Lo Preiato V, Salvagni S, Ricci C, Ardizzoni A, Pagotto U, Pelusi C. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature. Rev Endocr Metab Disord. 2021;22(2):337–49. https://doi.org/10.1007/s11154-020-09618-w.

Article  CAS  PubMed  Google Scholar 

Stamatouli AM, et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes. 2018;67(8):1471–80. https://doi.org/10.2337/dbi18-0002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeun R, et al. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy. 2023;15(6):417–28. https://doi.org/10.2217/imt-2021-0316.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bronner MB, Peeters MAC, Sattoe JNT, van Staa A. The impact of type 1 diabetes on young adults’ health-related quality of life. Health Qual Life Outcomes. 2020;18(1):137. https://doi.org/10.1186/s12955-020-01370-8.

Article  PubMed  PubMed Central  Google Scholar 

•• Barron CC, Stefanova I, Cha Y, Elsolh K, Zereshkian A, Gaafour N, McWhirter E. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11(8):e006500. https://doi.org/10.1136/jitc-2022-006500. Systematic review characterizing non-endocrine chronic irAEs across all cancer types.

Cappelli LC, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018;48(3):553–7.